Introduction {#sec1_1}
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In 1930, Mauriac \[[@B1]\] first described abnormal glycogen deposition, hepatomegaly and abnormal liver enzymes associated with growth retardation, delayed puberty, cushingoid features and hypercholesterolemia in children with uncontrolled type 1 diabetes mellitus (DM). Since then, it has been revealed that such hepatic glycogen accumulation can occur independently of the aforementioned extrahepatic manifestations of Mauriac syndrome. Over the years, this abnormality has been termed hepatic glycogenosis \[[@B2]\], liver glycogen storage \[[@B3]\], liver glycogenosis \[[@B4]\] and DM-associated glycogen storage hepatomegaly \[[@B5]\]. Most recently, Torbenson et al. \[[@B6]\] designated this entity as glycogenic hepatopathy (GH).

Although heavily documented, GH remains underrecognized. This is especially the case in the adult population, where the more common liver abnormality associated with uncontrolled DM is considered to be non-alcoholic fatty liver disease (NAFLD). The two are indistinguishable on liver ultrasound \[[@B7]\], often causing clinicians to misdiagnose GH as NAFLD. In the following, we add to the already sizeable collection of GH cases. This case identifies the challenge that generalists and specialists face when diagnosing GH, especially in the adult population.

Case Presentation {#sec1_2}
=================

A 21-year-old female with a history of celiac disease (CD) and uncontrolled type 1 DM with an average glycated hemoglobin (HbA1c) of 13.3% was transferred from an outside facility with bilateral upper quadrant abdominal pain and tender hepatomegaly on examination. The patient denied any diarrheal episodes and reported compliance to an outpatient gluten-free diet. At the outside facility, the initial presentation had been a pruritic facial rash with left ear swelling and dyspnea. Initial laboratory evaluation revealed aspartate transaminase (AST) 3,161 U/l and alanine aminotransferase (ALT) 590 U/l. High-dose methylprednisolone was administered intravenously for the presenting symptoms. Serum liver panel drawn 4 h later showed an increase in AST and ALT to \>4,202 and 973 U/l, respectively. Prothrombin time, total bilirubin and alkaline phosphatase were within normal limits, with a slight decrease in serum albumin level. Serum lactic acid was elevated with an anion gap metabolic acidosis and ketonuria. Computed tomography (CT) of the abdomen and pelvis with intravenous contrast revealed hepatomegaly with fatty infiltration of the liver as well as large bowel (from transverse to descending colon) and small bowel (mid and distal ileal loops) wall thickening with few mildly distended loops of small bowel, mild edema, and fluid within the central mesentery. Intravenous resuscitation with a bolus of normal saline was given.

After transfer to our facility, the patient was started on an insulin drip along with continuation of normal saline resuscitation. A liver ultrasound with Doppler was performed, showing identical hepatic abnormalities as those seen on CT. On hospital day 5, the lactic acid normalized. Serum transaminases still persisted, but did so in a fluctuating manner.

Laboratory testing for autoimmune, infectious and drug-induced hepatitis was unremarkable. A liver biopsy was performed on day 3 after admission, revealing enlarged pale hepatocytes with slight microvesicular steatosis and prominent glycogenated nuclei without any ballooning or inflammation (fig. [1](#F1){ref-type="fig"}). Trichrome staining failed to reveal increased collagen deposition or fibrosis, but periodic acid-Schiff staining showed intracytoplasmic glycogen inclusions which disappeared after diastase administration, confirming GH. For the remainder of the hospital stay, the rise and fall in liver function tests (LFTs) did not correlate with blood glucose levels.

With modest symptomatic improvement in abdominal pain and significant decrease in transaminases, the patient was discharged home. Upon follow-up 1 week later, symptoms were completely resolved, with normalization of LFTs.

Discussion {#sec1_3}
==========

With the sharp incline in transaminases, the possible differentials of abdominal pain and hepatomegaly include ischemic hepatitis and autoimmune hepatitis. Ischemic hepatitis can present with lactic acidosis, however, lactic acidosis is also seen with diabetic ketoacidosis \[[@B8], [@B9]\], which was also noted in our case.

Autoimmune hepatitis is also commonly seen with CD \[[@B10]\]. Moreover, a study performed in 1995 showed elevated LFTs in 40% of patients with undiagnosed and therefore untreated CD \[[@B11]\]. More recent inquiries have shown that transaminitis can be present in even treated cases \[[@B12]\]. Active CD exhibits a malabsorption pattern on CT causing the small bowel to appear dilated, fluid-filled and flaccid, causing telescoping and possible intussusception with large flatus-filled colon from excess gas production with fluid pluming in the right colon and encrusting of the right colonic wall \[[@B13]\]. The introductory CT in our case revealed distended loops of small bowel and edema to a mild degree, indicating adequate suppression of CD with gluten-free diet. In 2011, in a comprehensive review of the histologic characteristics of CD, Mounajjed et al. \[[@B14]\] showed liver biopsy results of 30 patients with CD. Of these patients, 19 had autoimmune-mediated liver disease (autoimmune hepatitis 9, primary sclerosing cholangitis 7, and primary biliary cirrhosis 3). The remaining 11 patients had cryptogenic hepatitis (5), hepatitis C (2), steatohepatitis (2) sarcoidosis (1) and T-cell lymphoma (1). The liver disease diagnosis preceded the CD diagnosis in all groups except for steatohepatitis. However, these patients do not typically have such a sharp elevation of LFTs as described in our case. Furthermore, a \>10-fold increase in liver enzymes has been commonly documented in many cases of GH, with a disproportionately greater rise in AST versus ALT observed in our case \[[@B2], [@B3], [@B15], [@B16], [@B17]\].

Individuals with NAFLD also have a higher prevalence of CD \[[@B18]\]. On liver biopsy, NAFLD-defining lesions include a certain degree of steatosis with lobular inflammation, portal inflammation, hepatocyte ballooning and/or fibrosis. Instead, the histologic characteristics of GH were seen in our case, specifically pale, swollen hepatocytes with glycogenated nuclei and positive periodic acid-Schiff-stained intracytoplasmic inclusions that disappear after digestion with diastase \[[@B6], [@B19]\]. Clinically, the two differ in that NAFLD is seen more in type 2 DM, happening as a result of insulin insensitivity from obesity and exhibiting the ability to progress to cirrhosis, while GH has occurred mostly with type 1 DM, with no evidence of progression to cirrhosis \[[@B6], [@B20]\]. Other than in uncontrolled type 1 DM, the use of high-dose corticosteroids has been identified as another precipitant of GH \[[@B21]\]. In our case, high-dose corticosteroid administration served as more of an exacerbating factor, causing serologic worsening.

The pathophysiology of GH involves glucose freely diffusing from the plasma into a hepatocyte where it is trapped by its conversion to glucose-6-phosphate by glucokinase followed by conversion to glycogen by glycogen synthase. Initially inactive, glycogen synthase is activated as a consequence of dephosphorylation by phosphatase. The concentration and activity of phosphatase depend on insulin and the presence of glucose, respectively \[[@B22], [@B23]\]. In essence, large amounts of both plasma glucose and insulin are needed for the development of GH, both of which are present in the setting of uncontrolled diabetes. A potential exacerbating factor are the frequent hypoglycemic episodes commonly seen in type 1 DM that are subsequently treated with glucose administration, further fueling glycogen formation and deposition \[[@B22]\]. Fridell et al. \[[@B24]\] confirmed this by showing complete clinical and histologic resolution of GH by establishing euglycemia without exogenous insulin via pancreatic transplantation. This explains the persistence of transaminitis despite achieving periods of normalized blood sugars with insulin therapy in our case.

Improving glycemic control is the mainstay of treatment for GH, with excellent prognosis in the form of complete symptomatic resolution as well as normalization of LFTs and liver size \[[@B3], [@B22], [@B23], [@B25], [@B26], [@B27], [@B28]\]. Recently, Cha et al. \[[@B15]\] challenged this and the notion that hyperglycemia from poor diabetes control and aggressive insulin therapy are the sole factors that drive GH. They documented three cases of GH, all of which exhibited resolution of transaminitis without aggressive insulin therapy or lowering of HbA1c. Upon further review, their first case did show biochemical resolution of GH with better glycemic control, however this happened without the HbA1c dropping below 11%. Our case is similar in that an improvement of just 0.6% in HbA1c led to symptomatic relief of abdominal pain and a decline of LFTs. No previous studies have been done on the degree of improvement in glycemic control needed in order to serologically and symptomatically resolve GH, potentially explaining this phenomenon.

As seen in many cases including ours, liver biopsy has served as the only means of definitely diagnosing GH \[[@B6], [@B17], [@B23], [@B25], [@B28]\]. However, non-invasive testing for diagnosis has been recently explored. Firstly, Sweetser and Kraichely \[[@B16]\] described the detection of GH via non-contrast CT, explaining that NAFLD results in a hypodense liver, while the liver of GH would be hyperdense. Murata et al. \[[@B29]\] argued that the liver on CT in GH can be hypodense due to co-existing acute liver injury, and subsequently recommended the addition of dual-echo magnetic resonance imaging to the radiologic evaluation.

In conclusion, recent advancements have been made in obtaining better means of diagnosing GH, which should lessen the current level of difficulty for practitioners during such a clinical scenario. The need for further investigations still exists to resolve recent arguments that are challenging what is known of GH.
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![**a** On this view, enlarged pale hepatocytes with slight microvesicular steatosis and prominent nuclei are seen. A portal triad can be visualized (arrow) and no significant inflammation or ballooned hepatocytes are seen. **b** A higher-power view readily shows glycogenated nuclei (arrows).](crg-0009-0221-g01){#F1}
